[ 1 ] Larsen CA, Dashwood RH. Suppression of Met activation in human colon cancer cells treated with (-)-epigallocatechin-3-gallate: minor role of hydrogen peroxide[J]. Biochem Biophys Res Commun, 2009, 389(3): 527-530.
[2]
[ 2 ] Zhu BH, Zhan WH, Li ZR, et al. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis[J]. World J Gastroenterol, 2007, 13(8): 1162-1169.
[3]
[ 3 ] Farabegoli F, Papi A, Bartolini G, et al. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line[J]. Phytomedicine, 2010, 17(5): 356-362.
[4]
[ 4 ] Shankar S, Ganapathy S, Hingorani SR, et al. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer[J]. Front Biosci, 2008, 13(1): 440-452.
[ 6 ] Suzuki Y, Miyoshi N, Isemura M. Health-promoting effect of green tea[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012,88(3): 88-101.
[7]
[ 7 ] M Chacko S, Thambi PT, Kuttan R, et a1. Beneficial effects of green tea: a literature review[J]. Chin Med, 2010, 5(1): 13.
[8]
[ 8 ] Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication[J]. Semin Diagn Pathol, 1993, 10(4): 302-313.
[9]
[ 9 ] Zhu BH, Zhan WH, He YL, et al. Epigallocatechin-3-gallate inhibits growth and angiogenesis of gastric cancer and its molecular mechanism[J]. World J gastroenterol, 2009, 12(1): 82-85.
[10]
Wu H, Xin Y, Xiao Y, et al. Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts[J]. Cancer Biother Radiopharm, 2012, 27(3): 204-209.
[11]
Fraga A, Ribeiro R, Medeiros R. Tumor hypoxia: the role of HIF[J]. Actas Urol Esp, 2009, 33(9): 941- 951.
[12]
Nakayama K. Cellular signal transduction of the hypoxia response[J]. J Bio Chem, 2009, 146(6): 757-765.
[13]
Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer[J]. Expert Rev Mol Med, 2009, 27(2): 11- 26.
[14]
Jubb A, Hillan K. Expression of HIF-1 alpha in human tumours[J]. J Clin Pathol, 2005, 58(12): 1344.
[15]
Przybylski M. A review of the current research on the role of bFGF and VEGF in angiogenesis[J]. J Wound Care, 2009, 18(12): 516-519.
[16]
Appelmann I, Liersch R, Kessler T, et a1. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy[J]. Recent Results Cancer Res, 2010, 180(3): 978-998.
